Evidence map›Paper›PMID 31019919›Full record

ArticleMolecular neuropsychiatry2019

Brain Gene Expression Pattern of Subjects with Completed Suicide and Comorbid Substance Use Disorder.

Brenda Cabrera, Nancy Monroy-Jaramillo, Gabriel Rodrigo Fries, Roberto Cuauhtemoc Mendoza-Morales, Fernando García-Dolores, Alejandra Mendoza-Larios, Carlos Diaz-Otañez, Consuelo Walss-Bass, David Colin Glahn, Patricia Ostrosky-Wegman and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular neuropsychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Molecular Changes Associated with Suicide.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Brenda CabreraGenomics of Psychiatric and Neurodegenerative Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico.
Nancy Monroy-JaramilloDepartment of Genetics, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Gabriel Rodrigo FriesDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Roberto Cuauhtemoc Mendoza-MoralesInstitute of Forensic Sciences (INCIFO), Mexico City, Mexico.
Fernando García-DoloresInstitute of Forensic Sciences (INCIFO), Mexico City, Mexico.
Alejandra Mendoza-LariosInstitute of Forensic Sciences (INCIFO), Mexico City, Mexico.
Carlos Diaz-OtañezInstitute of Forensic Sciences (INCIFO), Mexico City, Mexico.
Consuelo Walss-BassDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, Texas, USA.
David Colin GlahnDepartment of Psychiatry, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Patricia Ostrosky-WegmanBiomedical Research Institute, National Autonomous University of Mexico, Mexico City, Mexico.
Cristobal FresnoComputational Genomics Department, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico.
Humberto NicoliniGenomics of Psychiatric and Neurodegenerative Diseases Laboratory, National Institute of Genomic Medicine (INMEGEN), Mexico City, Mexico.
National Institute of Genomic Medicine · MXThe University of Texas Health Science Center at Houston · USInstituto Nacional de Neurología y Neurocirugía · MXUniversidad Nacional Autónoma de México · MXYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimAlthough individuals with substance use disorder (SUD) are at high risk of committing suicide, most studies of postmortem gene expression exclude subjects with SUD due to the potential confounding effect of drugs in the transcriptome. Thus, little is known about the gene expression profile in suicides with SUD. The identification of altered biological processes in suicides with SUD is crucial in the comprehension of the interaction between both pathologies.

methodsWe evaluated the gene expression profile in the dorsolateral prefrontal area of suicides and nonsuicides with and without SUD by microarrays.

resultsWe identified 222 differentially expressed genes, predominately enriched in cell proliferation in the comparison between suicides with and without SUD. When comparing the transcriptome of suicides with SUD to nonsuicides with SUD, we identified 550 differentially expressed genes, mainly enriched in oxidative phosphorylation. Differentially expressed genes (1,417) between suicides and nonsuicides without SUD were detected. Most of them were related to mitochondrial function.

conclusionInteraction between suicide and SUD seems to influence the expression of genes involved in glial proliferation and glutamatergic neurotransmission. These results highlight, for the first time, that suicides with SUD have a gene expression profile distinct from that of subjects with only one of these disorders.

Indexed as

Dorsolateral prefrontal cortexExpression studyMicroarrayPostmortemSubstance use disorderTranscriptomics

Identifiers

PMID31019919
PMCPMC6465692
OpenAlexW2900844209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.